期刊文献+

减低剂量地西他滨治疗骨髓增生异常综合征伴单系发育不良患者的疗效观察 被引量:3

Clinical observation on the treatment of myelodysplastic syndrome with single lineage dysplasia by dose-reduced decitabine
下载PDF
导出
摘要 目的:探讨减低剂量地西他滨治疗骨髓增生异常综合征伴单系发育不良(MDS-SLD)患者的临床疗效和安全性。方法:使用减低剂量地西他滨[15 mg/(m^2·d),连续5 d]治疗12例MDS-SLD患者,观察其疗效和不良反应。结果:2例(16.6%)获完全缓解,1例(8.3%)获部分缓解,5例(41.6%)达血液学改善,总反应率达66.6%。在5例可行细胞遗传学评估的患者中,1例(20.0%)获PR。Ⅳ级血液学毒性发生率50.0%,Ⅲ~Ⅳ级感染发生率33.3%,无Ⅲ~Ⅳ级出血,无Ⅲ~Ⅳ级恶心呕吐和Ⅲ~Ⅳ级肝功能损伤。中位随访时间16(2~32)个月,随访期间无患者死亡。结论:减低剂量地西他滨治疗骨髓增生异常综合征完全缓解及部分缓解率高,药物不良反应发生率低。 Objective:To observe the clinical effect of dose-reduced decitabine in the treatment of patients with myelodysplastic syndrome with single lineage dysplasia(MDS-SLD).Methods:Clinical data of 12 cases of MDS-SLD were collected,and all patients were treated by dose-reduced decitabine(15 mg/m^2 intravenously once daily for 5 days).The efficacy and side-effects of therapy in these patients were evaluated.Results:Of all 12 patients,2 cases(16.6%)achieved complete remission(CR),1 case achieved partial remission(8.3%),5 cases(41.6%)achieved hematologic improvement(HI),and the overall response rate(ORR)was 66.6%.Of the 5 cases in whom cytogenetic evaluation could be performed,1 case(20.0%)achieved partial cytogenetic remission.GradeⅣhematologic toxicity rate was 50.0%,and gradeⅢ-Ⅳinfection rate was 33.3%.No gradeⅢ-Ⅳbleeding,severe nausea and vomiting(gradeⅢ-Ⅳ)and liver injury(Ⅲ-Ⅳ)occurred.The median follow-up time was 16 months(2-32 months).At the end of follow-up,no patients were dead.Conclusion:In the treatment of MDS,the rate of CR and PR was high,and the incidence of adverse drug reactions was low.
作者 龚辉 陈姣 杜芳 周凌云 刘丹波 康春香 GONG Hui;CHEN Jiao;DU Fang;ZHOU Ling-yun;LIU Dan-bo;KANG Chun-xiang(Shenzhen Luohu District Peoples Hospital,Shenzhen 518001,China)
出处 《内科急危重症杂志》 2019年第2期107-109,共3页 Journal of Critical Care In Internal Medicine
基金 深科技创新2017(No:131)
关键词 骨髓增生异常综合征伴单系病态造血 地西他滨 减低剂量 临床效果 血液学毒性 Myelodysplastic syndrome with single lineage dysplasia Decitabine Dose reduction Clinical effect Hematologic toxicity
  • 相关文献

参考文献5

二级参考文献31

  • 1Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ]. Lyon, France : IARC, 2008.
  • 2Vardiman JW, Thiele J, Arber DA. , et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[ J]. Blood ,2009,114:937 - 951.
  • 3Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome : International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts[ J]. Haematologica ,2008,93 : 1712 - 1717.
  • 4Giagounidis AAN. Myelodysplasia or myelodysplastic syndrome? [ J]. Leuk Res,2009,33 : 1019.
  • 5杨崇礼.骨髓增生异常综合征[M]//邓家栋,杨崇礼,杨天楹等.邓家栋血液学.上海:上海科学技术出版社,2007:753.
  • 6Guoqing Wei,Wanmao Ni,Jen-wei Chiao,Zhen Cai,He Huang,Delong Liu.A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. Journal of Hematology & Oncology . 2011
  • 7Amuguleng Bai,Hiroshi Kojima,Mitsuo Hori,Nobuo Nara,Takuya Komeno,Yuichi Hasegawa,Haruhiko Ninomiya,Tsukasa Abe,Toshiro Nagasawa.Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells[J].Experimental Hematology.1999(2)
  • 8Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia . 1995
  • 9MarthaArellano,ElliottWinton,LinPan,LisaLima,MouradTighiouart,KapilBhalla,Leonard T.Heffner,JessicaNeely,DonaldHutcherson,MorganMcLemore,AmeliaLangston,H. JeanKhoury.High‐dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years[J]. Cancer . 2012 (2)
  • 10Si-Xuan Qian,Jian-Yong Li,Tian Tian,Yun-Feng Shen,Yuan-Qiang Jiang,Hua Lu,Han-Xin Wu,Su-Jiang Zhang,Wei Xu.Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia[J]. Leukemia Research . 2007 (10)

共引文献103

同被引文献29

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部